Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by WalkOverTheStrton May 15, 2021 9:03am
180 Views
Post# 33209581

RE:RE:RE:To All Shareholders

RE:RE:RE:To All ShareholdersGame Changer - Thank you for the response and context.  I've appreciated info folks like you have stated reagrding convos with Antibe. I've sent emails to IR and get the responses in a timely manner.  Every board has it's trolls / shorts that use false narratives and fear monger. I do not think those types of posters will respond and it may be not worth the time but good luck to you. 


Another aspect we are wittnessing on the board is malise and frustration (with some shorts / trolls, even me at times ;) on the pps not reflecting what many of us believe should be a more accurate market cap ($600M min). In many ways we are on the cusp of many positive catalysts (next partner, PH3 start, dosing study update, start of next drug in humans) but many of these events are in late 2021. So many prey on this deadzone stage we are in. Time and progress marches on and we all just need to be patient as Dan and mgmt will deliver. 


<< Previous
Bullboard Posts
Next >>